Pityriasis Folliculorum: Response to Topical Ivermectin

REFERENCES

1. Ayres S, Ayres S Jr. Demodectic eruptions (demodicidosis) in the human. 30 years’ experience with 2 commonly unrecognized entities: pityriasis folliculorum (Demodex) and acne rosacea (Demodex type). Arch Dermatol. 1961;83:816-27.
2. Ayers S Jr, Mihan R, Marks R, Harcourt-Webster JN. Demodex folliculorum in rosacea. Arch Dermatol. 1970;101(6):706-7.
3. Tinklepaugh AJ, Wilson BB. Pityriasis folliculorum: A novel therapy for a diagnostically challenging condition. J Am Acad Dermatol. 2013;69:276–277.
4. Zhao YE, Wu LP, Peng Y et al. Retrospective Analysis of the Association Between Demodex Infestation and Rosacea. Arch Dermatol. 2010;146(8):896-902.
5. Hsu CK, Hsu MML, Lee JYY. Demodicosis: a clinicopathological study. J Am Acad Dermatol. 2009;60(3):453- 462.
6. Yuan C, Wang XM, Guichard A et al. Comparison of reflectance confocal microscopy and standardized skin surface biopsy for three different lesions in a pityriasis folliculorum patient. Br J Dermatol. 2015; 172(5): 1440-2.
7. Chen W. Plewig G. Human demodicosis: revisit and a proposed classification. Br J Dermatol. 2014;170(6):1219-25.
8. Dominey A, Tschen J, Rosen T et al. Pityriasis folliculorum revisited. J Am Acad Dermatol. 1989;21(1):81-4.
9. Forton FM. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol. 2012 Jan;26(1):19-28.
10. Guerrero-Gonzalez GA, Herz-Ruelas ME, Gomez-Flores M et al. Crusted Demodicosis in an Immunocompetent Pediatric Patient. Case Rep Dermatol Med. 2014;2014: 458046.
11. Raedler L. Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea. Am Health Drug Benefits. 2015;8(Spec Feature): 122–125.
12. Stein GL, Kircik L, Fowler J et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13:316–323.
13. Soolantra (ivermectin) cream, 1%, for topical use [prescribing information]. Fort Worth, TX: Galderma Laboratories, LP; December 2014.
14. Fichtel JC, Wiggins AK, Lesher JL. Plaque-forming demodicidosis. J Am Acad Dermatol. 2005;52(2 Suppl 1):59-61.
15. Damian D, Rogers M. Demodex infestation in a child with leukaemia: treatment with ivermectin and permethrin. Int J Dermatol. 2003;42(9):724-6.
16. Karingaoglu Y, Bayram N, Aycan O et al. The clinical importance of demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol. 2004; 31(8):618-26.
17. Hasan M, Siddiqui FA, Naim M. Human demodicidosis. Ann Trop Med Public Health. 2008;1:70–1.
18. Jarmuda S, O’Reilly N, Zaba R, Jakubowicz O et al. Potential role of Demodex mites and bacteria in the induction of rosacea. J Med Microbiol. 2012;61(Pt 11):1504-10.
19. Aquilina C, Viraben R, Sire S. Ivermectin-responsive Demodex infestation during human immunodeficiency virus
20. Morsy TA, Morsy GH, Sanad EM. Eucalyptus globulus (camphor oil) in the treatment of human demodicidosis. J Egypt Soc Parasitol. 2002;32(3):797-803.
21. Gupta G, Daigle D, Gupta AK et al. Ivermectin 1% cream for rosacea. Skin therapy Lett. 2015:20(4):9-11.
22. Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol. 2005;44(12):981-8.
23. Deeks Ed. Ivermectin: A Review in Rosacea. Am J Clin Dermatol. 2015;16(5):447-52.
24. Taieb A, Ortonne JP, Ruzicka T et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103-10.

AUTHOR CORRESPONDENCE